Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017

Home/Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017

Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017

Research & Development (Pharma & Healthcare), Drug Discovery, Pharma & Healthcare

Publication ID:

GBI0517003

Publication Date:

May 09, 2017

Pages:

139

Publisher:

GBI Research

Region:

Global

$3,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the toxicology pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting, Chemotherapy Induced Neutropenia, Chemotherapy Induced Anemia, Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

These key indications are all common side effects of cancer chemotherapy treatment, and result in a substantial reduction in the patient’s quality of life. Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Chemotherapy-induced neutropenia is another very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. Chemotherapy-induced anemia symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. Finally, chemotherapy-induced peripheral neuropathy (CIPN) is a further potential side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems.

The size of these pipelines ranges from 16 in chemotherapy-induced anemia to 41 in chemotherapy-induced neutropenia and CIPN. In CINV and CIPN, there is a relatively diverse range of targets which are being studied, although most of these targets are neurotransmitter receptors. On the other hand, the pipelines for chemotherapy-induced neutropenia and anemia are far more limited in the range of molecular targets being studied.

Scope

- Which companies are the most active within the pipeline for toxicology therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of toxicology therapeutics?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 9
Introduction 10
Toxicology Cluster Chemotherapy Related Toxicity Report Coverage 10
Chemotherapy Induced Nausea and Vomiting – Overview 10
Chemotherapy Induced Neutropenia – Overview 10
Chemotherapy Induced Anemia – Overview 10
Chemotherapy Induced Peripheral Neuropathy – Overview 10
Therapeutics Development 11
Chemotherapy Induced Nausea and Vomiting 11
Chemotherapy Induced Neutropenia 15
Chemotherapy Induced Anemia 20
Chemotherapy Induced Peripheral Neuropathy 23
Therapeutics Assessment 30
Chemotherapy Induced Nausea and Vomiting 30
Chemotherapy Induced Neutropenia 37
Chemotherapy Induced Anemia 45
Chemotherapy Induced Peripheral Neuropathy 53
Companies Involved in Therapeutics Development 61
Chemotherapy Induced Nausea and Vomiting 61
Chemotherapy Induced Neutropenia 70
Chemotherapy Induced Anemia 82
Chemotherapy Induced Peripheral Neuropathy 89
Dormant Projects 103
Chemotherapy Induced Nausea and Vomiting 103
Chemotherapy Induced Neutropenia 104
Chemotherapy Induced Anemia 105
Chemotherapy Induced Peripheral Neuropathy 106
Discontinued Products 107
Chemotherapy Induced Nausea and Vomiting 107
Chemotherapy Induced Neutropenia 107
Chemotherapy Induced Anemia 108
Chemotherapy Induced Peripheral Neuropathy 108
Product Development Milestones 109
Chemotherapy Induced Nausea and Vomiting 109
Chemotherapy Induced Neutropenia 116
Chemotherapy Induced Anemia 125
Chemotherapy Induced Peripheral Neuropathy 131
Appendix 138
Methodology 138
Coverage 138
Secondary Research 138
Primary Research 138
Expert Panel Validation 138
Contact Us 139
Disclaimer 139

List of Tables
List of Tables
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting 11
Number of Products under Development by Companies, Chemotherapy Induced Nausea and Vomiting 13
Products under Development by Companies, Chemotherapy Induced Nausea and Vomiting 14
Number of Products under Development for Chemotherapy Induced Neutropenia 16
Number of Products under Development by Companies, Chemotherapy Induced Neutropenia 17
Number of Products under Development by Universities/Institutes, Chemotherapy Induced Neutropenia 17
Products under Development by Companies, Chemotherapy Induced Neutropenia 18
Products under Development by Universities/Institutes, Chemotherapy Induced Neutropenia 20
Number of Products under Development for Chemotherapy Induced Anemia 20
Number of Products under Development by Companies, Chemotherapy Induced Anemia 21
Products under Development by Companies, Chemotherapy Induced Anemia 22
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy 23
Number of Products under Development by Companies, Chemotherapy Induced Peripheral Neuropathy 25
Number of Products under Development by Universities/Institutes, Chemotherapy Induced Peripheral Neuropathy 26
Products under Development by Companies, Chemotherapy Induced Peripheral Neuropathy 27
Products under Development by Universities/Institutes, Chemotherapy Induced Peripheral Neuropathy 29
Number of Products by Stage and Target, Chemotherapy Induced Nausea and Vomiting 31
Number of Products by Stage and Mechanism of Action, Chemotherapy Induced Nausea and Vomiting 33
Number of Products by Stage and Route of Administration, Chemotherapy Induced Nausea and Vomiting 35
Number of Products by Stage and Molecule Type, Chemotherapy Induced Nausea and Vomiting 36
Number of Products by Stage and Target, Chemotherapy Induced Neutropenia 38
Number of Products by Stage and Mechanism of Action, Chemotherapy Induced Neutropenia 40
Number of Products by Stage and Route of Administration, Chemotherapy Induced Neutropenia 42
Number of Products by Stage and Molecule Type, Chemotherapy Induced Neutropenia 44
Number of Products by Stage and Target, Chemotherapy Induced Anemia 46
Number of Products by Stage and Mechanism of Action, Chemotherapy Induced Anemia 48
Number of Products by Stage and Route of Administration, Chemotherapy Induced Anemia 50
Number of Products by Stage and Molecule Type, Chemotherapy Induced Anemia 52
Number of Products by Stage and Target, Chemotherapy Induced Peripheral Neuropathy 54
Number of Products by Stage and Mechanism of Action, Chemotherapy Induced Peripheral Neuropathy 56
Number of Products by Stage and Route of Administration, Chemotherapy Induced Peripheral Neuropathy 58
Number of Products by Stage and Molecule Type, Chemotherapy Induced Peripheral Neuropathy 60
Chemotherapy Induced Nausea and Vomiting – Pipeline by Acacia Pharma Ltd 61
Chemotherapy Induced Nausea and Vomiting – Pipeline by Aphios Corp 61
Chemotherapy Induced Nausea and Vomiting – Pipeline by Astellas Pharma Inc 62
Chemotherapy Induced Nausea and Vomiting – Pipeline by Camurus AB 62
Chemotherapy Induced Nausea and Vomiting – Pipeline by Daewoong Pharmaceutical Co Ltd 63
Chemotherapy Induced Nausea and Vomiting – Pipeline by Heron Therapeutics Inc 63
Chemotherapy Induced Nausea and Vomiting – Pipeline by INSYS Therapeutics Inc 64
Chemotherapy Induced Nausea and Vomiting – Pipeline by Kyowa Hakko Kirin Co Ltd 64
Chemotherapy Induced Nausea and Vomiting – Pipeline by MannKind Corp 65
Chemotherapy Induced Nausea and Vomiting – Pipeline by Medlab Clinical Ltd 65
Chemotherapy Induced Nausea and Vomiting – Pipeline by Nemus Bioscience Inc 66
Chemotherapy Induced Nausea and Vomiting – Pipeline by RedHill Biopharma Ltd 66
Chemotherapy Induced Nausea and Vomiting – Pipeline by Serina Therapeutics Inc 67
Chemotherapy Induced Nausea and Vomiting – Pipeline by SoluBest Ltd 67
Chemotherapy Induced Nausea and Vomiting – Pipeline by Suda Ltd 68
Chemotherapy Induced Nausea and Vomiting – Pipeline by Tesaro Inc 68
Chemotherapy Induced Nausea and Vomiting – Pipeline by Therapix Biosciences Ltd 69
Chemotherapy Induced Neutropenia – Pipeline by Apotex Inc 70
Chemotherapy Induced Neutropenia – Pipeline by Biocon Ltd 70
Chemotherapy Induced Neutropenia – Pipeline by Biogenomics Ltd 71
Chemotherapy Induced Neutropenia – Pipeline by Bolder Biotechnology Inc 71
Chemotherapy Induced Neutropenia – Pipeline by Cellerant Therapeutics Inc 72
Chemotherapy Induced Neutropenia – Pipeline by Chong Kun Dang Pharmaceutical Corp 72
Chemotherapy Induced Neutropenia – Pipeline by Cinfa Biotech SL 73
Chemotherapy Induced Neutropenia – Pipeline by Dr. Reddy's Laboratories Ltd 73
Chemotherapy Induced Neutropenia – Pipeline by Gene Techno Science Co Ltd 74
Chemotherapy Induced Neutropenia – Pipeline by Generon (Shanghai) Corp Ltd 74
Chemotherapy Induced Neutropenia – Pipeline by Genexine Inc 75
Chemotherapy Induced Neutropenia – Pipeline by GlycoMimetics Inc 75
Chemotherapy Induced Neutropenia – Pipeline by Hanmi Pharmaceuticals Co Ltd 76
Chemotherapy Induced Neutropenia – Pipeline by Mycenax Biotech Inc 76
Chemotherapy Induced Neutropenia – Pipeline by Myelo Therapeutics GmbH 77
Chemotherapy Induced Neutropenia – Pipeline by Nohla Therapeutics Inc 77
Chemotherapy Induced Neutropenia – Pipeline by Octapharma AG 78
Chemotherapy Induced Neutropenia – Pipeline by Pfenex Inc 78
Chemotherapy Induced Neutropenia – Pipeline by Pfizer Inc 79
Chemotherapy Induced Neutropenia – Pipeline by Reliance Life Sciences Pvt Ltd 79
Chemotherapy Induced Neutropenia – Pipeline by Richter Gedeon Nyrt 80
Chemotherapy Induced Neutropenia – Pipeline by Sandoz International GmbH 80
Chemotherapy Induced Neutropenia – Pipeline by USV Pvt Ltd 81
Chemotherapy Induced Anemia – Pipeline by 3SBio Inc 82
Chemotherapy Induced Anemia – Pipeline by Chong Kun Dang Pharmaceutical Corp 82
Chemotherapy Induced Anemia – Pipeline by Dr. Reddy's Laboratories Ltd 83
Chemotherapy Induced Anemia – Pipeline by Galenica Ltd 83
Chemotherapy Induced Anemia – Pipeline by Novartis AG 84
Chemotherapy Induced Anemia – Pipeline by Panacea Biotec Ltd 84
Chemotherapy Induced Anemia – Pipeline by Pfizer Inc 85
Chemotherapy Induced Anemia – Pipeline by PharmaEssentia Corp 85
Chemotherapy Induced Anemia – Pipeline by PhytoHealth Corp 86
Chemotherapy Induced Anemia – Pipeline by Pieris Pharmaceuticals Inc 86
Chemotherapy Induced Anemia – Pipeline by SBI Pharmaceuticals Co Ltd 87
Chemotherapy Induced Anemia – Pipeline by Therapure Biopharma Inc 87
Chemotherapy Induced Anemia – Pipeline by Tolero Pharmaceuticals Inc 88
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Achelios Therapeutics Inc 89
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Advinus Therapeutics Ltd 89
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Apollo Endosurgery Inc 90
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Aptinyx Inc 90
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Asahi Kasei Pharma Corp 91
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Can-Fite BioPharma Ltd 91
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Celgene Corp 92
Chemotherapy Induced Peripheral Neuropathy – Pipeline by DermaXon LLC 92
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Eisai Co Ltd 93
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Immune Pharmaceuticals Inc 93
Chemotherapy Induced Peripheral Neuropathy – Pipeline by INSYS Therapeutics Inc 94
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Kineta Inc 94
Chemotherapy Induced Peripheral Neuropathy – Pipeline by KPI Therapeutics Inc 95
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Krenitsky Pharmaceuticals Inc 95
Chemotherapy Induced Peripheral Neuropathy – Pipeline by MAKScientific LLC 96
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Metys Pharmaceuticals AG 96
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Midatech Pharma US Inc 97
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Mundipharma International Ltd 97
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Nemus Bioscience Inc 98
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Neurocentrx Pharma Ltd 98
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Panacea Pharmaceuticals Inc 99
Chemotherapy Induced Peripheral Neuropathy – Pipeline by PeriphaGen Inc 99
Chemotherapy Induced Peripheral Neuropathy – Pipeline by PharmatrophiX Inc 100
Chemotherapy Induced Peripheral Neuropathy – Pipeline by PledPharma AB 100
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Sova Pharmaceuticals Inc 101
Chemotherapy Induced Peripheral Neuropathy – Pipeline by Virobay Inc 101
Chemotherapy Induced Peripheral Neuropathy – Pipeline by WEX Pharmaceuticals Inc 102
Chemotherapy Induced Nausea and Vomiting – Dormant Projects 103
Chemotherapy Induced Neutropenia – Dormant Projects 104
Chemotherapy Induced Anemia – Dormant Projects 105
Chemotherapy Induced Peripheral Neuropathy – Dormant Projects 106
Chemotherapy Induced Nausea and Vomiting – Discontinued Products 107
Chemotherapy Induced Neutropenia – Discontinued Products 107
Chemotherapy Induced Anemia – Discontinued Products 108
Chemotherapy Induced Peripheral Neuropathy – Discontinued Products 108

List of Figures
List of Figures
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting 11
Number of Products under Development by Companies, Chemotherapy Induced Nausea and Vomiting 12
Number of Products under Development for Chemotherapy Induced Neutropenia 15
Number of Products under Development by Companies, Chemotherapy Induced Neutropenia 16
Number of Products under Development for Chemotherapy Induced Anemia 20
Number of Products under Development by Companies, Chemotherapy Induced Anemia 21
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy 23
Number of Products under Development by Companies, Chemotherapy Induced Peripheral Neuropathy 24
Number of Products under Development by Universities/Institutes, Chemotherapy Induced Peripheral Neuropathy 26
Number of Products by Targets, Chemotherapy Induced Nausea and Vomiting 30
Number of Products by Stage and Targets, Chemotherapy Induced Nausea and Vomiting 30
Number of Products by Mechanism of Actions, Chemotherapy Induced Nausea and Vomiting 32
Number of Products by Stage and Mechanism of Actions, Chemotherapy Induced Nausea and Vomiting 32
Number of Products by Top 10 Routes of Administration, Chemotherapy Induced Nausea and Vomiting 34
Number of Products by Stage and Top 10 Routes of Administration, Chemotherapy Induced Nausea and Vomiting 34
Number of Products by Stage and Molecule Types, Chemotherapy Induced Nausea and Vomiting 36
Number of Products by Targets, Chemotherapy Induced Neutropenia 37
Number of Products by Stage and Targets, Chemotherapy Induced Neutropenia 37
Number of Products by Mechanism of Actions, Chemotherapy Induced Neutropenia 39
Number of Products by Stage and Mechanism of Actions, Chemotherapy Induced Neutropenia 39
Number of Products by Routes of Administration, Chemotherapy Induced Neutropenia 41
Number of Products by Stage and Routes of Administration, Chemotherapy Induced Neutropenia 41
Number of Products by Molecule Types, Chemotherapy Induced Neutropenia 43
Number of Products by Stage and Molecule Types, Chemotherapy Induced Neutropenia 43
Number of Products by Targets, Chemotherapy Induced Anemia 45
Number of Products by Stage and Targets, Chemotherapy Induced Anemia 45
Number of Products by Mechanism of Actions, Chemotherapy Induced Anemia 47
Number of Products by Stage and Mechanism of Actions, Chemotherapy Induced Anemia 47
Number of Products by Routes of Administration, Chemotherapy Induced Anemia 49
Number of Products by Stage and Routes of Administration, Chemotherapy Induced Anemia 49
Number of Products by Molecule Types, Chemotherapy Induced Anemia 51
Number of Products by Stage and Molecule Types, Chemotherapy Induced Anemia 51
Number of Products by Top 10 Targets, Chemotherapy Induced Peripheral Neuropathy 53
Number of Products by Stage and Top 10 Targets, Chemotherapy Induced Peripheral Neuropathy 53
Number of Products by Top 10 Mechanism of Actions, Chemotherapy Induced Peripheral Neuropathy 55
Number of Products by Stage and Top 10 Mechanism of Actions, Chemotherapy Induced Peripheral Neuropathy 55
Number of Products by Routes of Administration, Chemotherapy Induced Peripheral Neuropathy 57
Number of Products by Stage and Routes of Administration, Chemotherapy Induced Peripheral Neuropathy 57
Number of Products by Molecule Types, Chemotherapy Induced Peripheral Neuropathy 59
Number of Products by Stage and Molecule Types, Chemotherapy Induced Peripheral Neuropathy 59

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".